# W Marston Linehan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1429121/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 323 papers | 40,210 citations | 2538 96 h-index | 2675 193 g-index |
| 332 all docs | 332 docs citations | 332 times ranked | 28199 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Identification of the von Hippel-Lindau disease tumor suppressor gene. Science, 1993, 260, 1317-1320. | 6.0 | 2,723 |
| 2 | Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nature Genetics, 1997, 16, 68-73. | 9.4 | 1,461 |
| 3 | von Hippel-Lindau disease. Lancet, The, 2003, 361, 2059-2067. | 6.3 | 1,322 |
| 4 | Comparison of MR/Ultrasound Fusionâ€“Guided Biopsy With Ultrasound-Guided Biopsy for the Diagnosis of Prostate Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 390. | 3.8 | 1,267 |
| 5 | Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature, 2012, 481, 385-388. | 13.7 | 1,074 |
| 6 | Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. New England Journal of Medicine, 2016, 374, 135-145. | 13.9 | 1,040 |
| 7 | Biochemical Diagnosis of Pheochromocytoma. JAMA - Journal of the American Medical Association, 2002, 287, 1427-34. | 3.8 | 994 |
| 8 | HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: Novel role of fumarate in regulation of HIF stability. Cancer Cell, 2005, 8, 143-153. | 7.7 | 843 |
| 9 | Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-DubÃ© syndrome. Cancer Cell, 2002, 2, 157-164. | 7.7 | 833 |
| 10 | The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma. Cancer Cell, 2014, 26, 319-330. | 7.7 | 665 |
| 11 | The genetic basis of kidney cancer: a metabolic disease. Nature Reviews Urology, 2010, 7, 277-285. | 1.9 | 634 |
| 12 | Mutations in the Fumarate Hydratase Gene Cause Hereditary Leiomyomatosis and Renal Cell Cancer in Families in North America. American Journal of Human Genetics, 2003, 73, 95-106. | 2.6 | 563 |
| 13 | Renal Tumors in the Birt-Hogg-DubÃ© Syndrome. American Journal of Surgical Pathology, 2002, 26, 1542-1552. | 2.1 | 544 |
| 14 | Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: Correlations with phenotype. Human Mutation, 1995, 5, 66-75. | 1.1 | 526 |
| 15 | The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Reports, 2018, 23, 313-326.e5. | 2.9 | 523 |
| 16 | Recent Advances in Genetics, Diagnosis, Localization, and Treatment of Pheochromocytoma. Annals of Internal Medicine, 2001, 134, 315. | 2.0 | 512 |
| 17 | Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors. Clinical Cancer Research, 2008, 14, 4726-4734. | 3.2 | 503 |
| 18 | Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene, 1999, 18, 2343-2350. | 2.6 | 487 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Human Mutation, 1998, 12, 417-423. | 1.1 | 452 |
| 20 | The Genetic Basis of Cancer of the Kidney. Journal of Urology, 2003, 170, 2163-2172. | 0.2 | 447 |
| 21 | Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Human Mutation, 1996, 8, 348-357. | 1.1 | 436 |
| 22 | Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma. Cell, 2019, 179, 964-983.e31. | 13.5 | 430 |
| 23 | Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 15552-15557. | 3.3 | 427 |
| 24 | The contribution of VHL substrate binding and HIF1-Î± to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell, 2002, 1, 247-255. | 7.7 | 421 |
| 25 | Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma. Journal of Clinical Oncology, 2013, 31, 181-186. | 0.8 | 401 |
| 26 | Germline BHD-Mutation Spectrum and Phenotype Analysis of a Large Cohort of Families with Birt-Hogg-DubÃ© Syndrome. American Journal of Human Genetics, 2005, 76, 1023-1033. | 2.6 | 363 |
| 27 | The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications. Nature Reviews Urology, 2019, 16, 539-552. | 1.9 | 357 |
| 28 | Birt-Hogg-DubÃ© Syndrome, a Genodermatosis Associated with Spontaneous Pneumothorax and Kidney Neoplasia, Maps to Chromosome 17p11.2. American Journal of Human Genetics, 2001, 69, 876-882. | 2.6 | 355 |
| 29 | Lung Cysts, Spontaneous Pneumothorax, and Genetic Associations in 89 Families with Birt-Hogg-DubÃ© Syndrome. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 1044-1053. | 2.5 | 318 |
| 30 | High Frequency ofSDHBGermline Mutations in Patients with Malignant Catecholamine-Producing Paragangliomas: Implications for Genetic Testing. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4505-4509. | 1.8 | 299 |
| 31 | Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma. Oncogene, 1997, 15, 2233-2239. | 2.6 | 298 |
| 32 | Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas. Nature Genetics, 1998, 20, 66-69. | 9.4 | 291 |
| 33 | Hereditary Papillary Renal Cell Carcinoma. Journal of Urology, 1994, 151, 561-566. | 0.2 | 289 |
| 34 | Measurements of Plasma Methoxytyramine, Normetanephrine, and Metanephrine as Discriminators of Different Hereditary Forms of Pheochromocytoma. Clinical Chemistry, 2011, 57, 411-420. | 1.5 | 282 |
| 35 | Oxidation of Alpha-Ketoglutarate Is Required for Reductive Carboxylation in Cancer Cells with Mitochondrial Defects. Cell Reports, 2014, 7, 1679-1690. | 2.9 | 281 |
| 36 | Pheochromocytomas in von Hippel-Lindau Syndrome and Multiple Endocrine Neoplasia Type 2 Display Distinct Biochemical and Clinical Phenotypes. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1999-2008. | 1.8 | 262 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | EVALUATION AND MANAGEMENT OF RENAL TUMORS IN THE BIRT-HOGG-DUBÃ‰ SYNDROME. Journal of Urology, 2005, 173, 1482-1486. | 0.2 | 260 |
| 38 | Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment. Familial Cancer, 2014, 13, 637-644. | 0.9 | 251 |
| 39 | Proteomic analysis of laser capture microdissected human prostate cancer andin vitro prostate cell lines. Electrophoresis, 2000, 21, 2235-2242. | 1.3 | 246 |
| 40 | Multiple Neuroendocrine Tumors of the Pancreas in von Hippel-Lindau Disease Patients. American Journal of Pathology, 1998, 153, 223-231. | 1.9 | 243 |
| 41 | Hereditary and Sporadic Papillary Renal Carcinomas with c-met Mutations Share a Distinct Morphological Phenotype. American Journal of Pathology, 1999, 155, 517-526. | 1.9 | 243 |
| 42 | Hereditary Leiomyomatosis and Renal Cell Cancer: A Syndrome Associated With an Aggressive Form of Inherited Renal Cancer. Journal of Urology, 2007, 177, 2074-2080. | 0.2 | 235 |
| 43 | CLINICAL AND GENETIC CHARACTERIZATION OF PHEOCHROMOCYTOMA IN VON HIPPEL-LINDAU FAMILIES: COMPARISON WITH SPORADIC PHEOCHROMOCYTOMA GIVES INSIGHT INTO NATURAL HISTORY OF PHEOCHROMOCYTOMA. Journal of Urology, 1999, 162, 659-664. | 0.2 | 233 |
| 44 | Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine tumors (PNETs). Surgery, 2007, 142, 814-818.e2. | 1.0 | 232 |
| 45 | RENAL CANCER IN FAMILIES WITH HEREDITARY RENAL CANCER: PROSPECTIVE ANALYSIS OF A TUMOR SIZE THRESHOLD FOR RENAL PARENCHYMAL SPARING SURGERY. Journal of Urology, 1999, 161, 1475-1479. | 0.2 | 229 |
| 46 | Multiparametric Magnetic Resonance Imaging and Ultrasound Fusion Biopsy Detect Prostate Cancer in Patients with Prior Negative Transrectal Ultrasound Biopsies. Journal of Urology, 2012, 188, 2152-2157. | 0.2 | 227 |
| 47 | Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers. Nature Reviews Urology, 2014, 11, 465-475. | 1.9 | 227 |
| 48 | Kidney-Targeted Birt-Hogg-Dube Gene Inactivation in a Mouse Model: Erk1/2 and Akt-mTOR Activation, Cell Hyperproliferation, and Polycystic Kidneys. Journal of the National Cancer Institute, 2008, 100, 140-154. | 3.0 | 223 |
| 49 | High Frequency of Somatic Frameshift BHD Gene Mutations in Birt-Hogg-DubÃ©â€“Associated Renal Tumors. Journal of the National Cancer Institute, 2005, 97, 931-935. | 3.0 | 213 |
| 50 | Fumarate Hydratase Deficiency in Renal Cancer Induces Glycolytic Addiction and Hypoxia-Inducible Transcription Factor 1Î± Stabilization by Glucose-Dependent Generation of Reactive Oxygen Species. Molecular and Cellular Biology, 2009, 29, 4080-4090. | 1.1 | 212 |
| 51 | Succinate Dehydrogenase Kidney Cancer: An Aggressive Example of the Warburg Effect in Cancer. Journal of Urology, 2012, 188, 2063-2071. | 0.2 | 211 |
| 52 | Hereditary Renal Cancers. Radiology, 2003, 226, 33-46. | 3.6 | 210 |
| 53 | Robotic Partial Nephrectomy for Complex Renal Tumors: Surgical Technique. European Urology, 2008, 53, 514-523. | 0.9 | 210 |
| 54 | Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 18722-18727. | 3.3 | 203 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Genetic basis of kidney cancer: Role of genomics for the development of disease-based therapeutics. Genome Research, 2012, 22, 2089-2100. | 2.4 | 202 |
| 56 | PARENCHYMAL SPARING SURGERY IN PATIENTS WITH HEREDITARY RENAL CELL CARCINOMA: 10-YEAR EXPERIENCE. Journal of Urology, 2001, 165, 777-781. | 0.2 | 198 |
| 57 | The Glycolytic Shift in Fumarate-Hydratase-Deficient Kidney Cancer Lowers AMPK Levels, Increases Anabolic Propensities and Lowers Cellular Iron Levels. Cancer Cell, 2011, 20, 315-327. | 7.7 | 190 |
| 58 | Correlation of Magnetic Resonance Imaging Tumor Volume with Histopathology. Journal of Urology, 2012, 188, 1157-1163. | 0.2 | 188 |
| 59 | Genetic Basis of Cancer of the Kidney. Clinical Cancer Research, 2004, 10, 6282S-6289S. | 3.2 | 187 |
| 60 | THE RELATIONSHIP BETWEEN RENAL TUMOR SIZE AND METASTASES IN PATIENTS WITH VON HIPPEL-LINDAU DISEASE. Journal of Urology, 2004, 172, 63-65. | 0.2 | 181 |
| 61 | Sarcomatoid Renal Cell Carcinoma: A Comprehensive Review of the Biology and Current Treatment Strategies. Oncologist, 2012, 17, 46-54. | 1.9 | 177 |
| 62 | Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-DubÃ© syndrome. Cancer Epidemiology Biomarkers and Prevention, 2002, 11, 393-400. | 1.1 | 177 |
| 63 | Original Articles: Kidney Cancer: Hereditary Papillary Renal Cell Carcinoma: Clinical Studies in 10 Families. Journal of Urology, 1995, 153, 907-912. | 0.2 | 176 |
| 64 | Molecular genetics and clinical features of Birtâ€“Hoggâ€“DubÃ© syndrome. Nature Reviews Urology, 2015, 12, 558-569. | 1.9 | 175 |
| 65 | Molecular Pathways: Fumarate Hydratase-Deficient Kidney Cancerâ€”Targeting the Warburg Effect in Cancer. Clinical Cancer Research, 2013, 19, 3345-3352. | 3.2 | 172 |
| 66 | Prevalence of Microscopic lesions in Grossly Normal Renal Parenchyma from Patients with von Hippel-Lindau Disease, Sporadic Renal Cell Carcinoma and No Renal Disease: Clinical Implications. Journal of Urology, 1995, 154, 2010-2015. | 0.2 | 170 |
| 67 | Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma. Endocrine-Related Cancer, 2010, 18, 97-111. | 1.6 | 169 |
| 68 | Von Hippel-Lindau (VHL) Inactivation in Sporadic Clear Cell Renal Cancer: Associations with Germline VHL Polymorphisms and Etiologic Risk Factors. PLoS Genetics, 2011, 7, e1002312. | 1.5 | 168 |
| 69 | Identification and characterization of a novel folliculin-interacting protein FNIP2. Gene, 2008, 415, 60-67. | 1.0 | 163 |
| 70 | The Metabolic Basis of Kidney Cancer. Cancer Discovery, 2019, 9, 1006-1021. | 7.7 | 163 |
| 71 | LACK OF RETROPERITONEAL LYMPHADENOPATHY PREDICTS SURVIVAL OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA. Journal of Urology, 2001, 166, 68-72. | 0.2 | 159 |
| 72 | Molecular Diagnosis and Therapy of Kidney Cancer. Annual Review of Medicine, 2010, 61, 329-343. | 5.0 | 154 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Robotic Partial Nephrectomy for Renal Hilar Tumors: A Multi-Institutional Analysis. Journal of Urology, 2008, 180, 2353-2356. | 0.2 | 147 |
| 74 | Inactivation of the FLCN Tumor Suppressor Gene Induces TFE3 Transcriptional Activity by Increasing Its Nuclear Localization. PLoS ONE, 2010, 5, e15793. | 1.1 | 146 |
| 75 | Rapid protein display profiling of cancer progression directly from human tissue using a protein biochip. Drug Development Research, 2000, 49, 34-42. | 1.4 | 144 |
| 76 | Characterization of the Renal Pathology of a Familial Form of Renal Cell Carcinoma Associated With Von Hippel-Lindau Disease: Clinical and Molecular Genetic Implications. Journal of Urology, 1995, 153, 22-26. | 0.2 | 143 |
| 77 | A Novel Germline Mutation in BAP1 Predisposes to Familial Clear-Cell Renal Cell Carcinoma. Molecular Cancer Research, 2013, 11, 1061-1071. | 1.5 | 135 |
| 78 | Defining Early-Onset Kidney Cancer: Implications for Germline and Somatic Mutation Testing and Clinical Management. Journal of Clinical Oncology, 2014, 32, 431-437. | 0.8 | 135 |
| 79 | FLCN : The causative gene for Birt-Hogg-DubÃ© syndrome. Gene, 2018, 640, 28-42. | 1.0 | 133 |
| 80 | Regression of Metastatic Renal Cell Carcinoma After Cytoreductive Nephrectomy. Journal of Urology, 1993, 150, 463-466. | 0.2 | 132 |
| 81 | The metabolic basis of kidney cancer. Seminars in Cancer Biology, 2013, 23, 46-55. | 4.3 | 132 |
| 82 | Identification of the Genes for Kidney Cancer: Opportunity for Disease-Specific Targeted Therapeutics. Clinical Cancer Research, 2007, 13, 671s-679s. | 3.2 | 131 |
| 83 | UOK 262 cell line, fumarate hydratase deficient (FHâ^'/FHâ^') hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. Cancer Genetics and Cytogenetics, 2010, 196, 45-55. | 1.0 | 131 |
| 84 | FAMILIAL RENAL ONCOCYTOMA: CLINICOPATHOLOGICAL STUDY OF 5 FAMILIES. Journal of Urology, 1998, 160, 335-340. | 0.2 | 127 |
| 85 | Expression of Birtâ€"Hoggâ€"DubÃ© gene mRNA in normal and neoplastic human tissues. Modern Pathology, 2004, 17, 998-1011. | 2.9 | 124 |
| 86 | CYTOREDUCTIVE SURGERY BEFORE HIGH DOSE INTERLEUKIN-2 BASED THERAPY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA. Journal of Urology, 1997, 158, 1675-1678. | 0.2 | 120 |
| 87 | Focus on kidney cancer. Cancer Cell, 2004, 6, 223-228. | 7.7 | 119 |
| 88 | EARLY ONSET HEREDITARY PAPILLARY RENAL CARCINOMA: GERMLINE MISSENSE MUTATIONS IN THE TYROSINE KINASE DOMAIN OF THE MET PROTO-ONCOGENE. Journal of Urology, 2004, 172, 1256-1261. | 0.2 | 115 |
| 89 | Hereditary leiomyomatosis and renal cell carcinoma. International Journal of Nephrology and Renovascular Disease, 2014, 7, 253. | 0.8 | 112 |
| 90 | Dual-color, Break-apart FISH Assay on Paraffin-embedded Tissues as an Adjunct to Diagnosis of Xp11 Translocation Renal Cell Carcinoma and Alveolar Soft Part Sarcoma. American Journal of Surgical Pathology, 2010, 34, 757-766. | 2.1 | 111 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Decreased expression of the pro-apoptotic protein Par-4 in renal cell carcinoma. Oncogene, 1999, 18, 1205-1208. | 2.6 | 108 |
| 92 | Genetic predisposition to kidney cancer. Seminars in Oncology, 2016, 43, 566-574. | 0.8 | 107 |
| 93 | INTERLEUKIN-2 BASED IMMUNOTHERAPY FOR METASTATIC RENAL CELL CARCINOMA WITH THE KIDNEY IN PLACE. Journal of Urology, 1999, 162, 43-45. | 0.2 | 102 |
| 94 | Surgical Management of Pheochromocytoma with the Use of Metyrosine. Annals of Surgery, 1990, 212, 621-628. | 2.1 | 101 |
| 95 | Hereditary kidney cancer. Cancer, 2009, 115, 2252-2261. | 2.0 | 101 |
| 96 | Translocation Renal Cell Carcinomas in Adults. American Journal of Surgical Pathology, 2012, 36, 654-662. | 2.1 | 98 |
| 97 | MANAGEMENT OF HEREDITARY PHEOCHROMOCYTOMA IN VON HIPPEL-LINDAU KINDREDS WITH PARTIAL ADRENALECTOMY. Journal of Urology, 1999, 161, 395-398. | 0.2 | 97 |
| 98 | Epididymal cystadenomas in von Hippel-Lindau disease. Urology, 1997, 49, 926-931. | 0.5 | 96 |
| 99 | SDHB-Deficient Cancers: The Role of Mutations That Impair Iron Sulfur Cluster Delivery. Journal of the National Cancer Institute, 2016, 108, djv287. | 3.0 | 92 |
| 100 | PREVALENCE OF MICROSCOPIC TUMORS IN NORMAL APPEARING RENAL PARENCHYMA OF PATIENTS WITH HEREDITARY PAPILLARY RENAL CANCER. Journal of Urology, 2000, 163, 431-433. | 0.2 | 91 |
| 101 | Alternative splicing of the cell fate determinant Numb in hepatocellular carcinoma. Hepatology, 2015, 62, 1122-1131. | 3.6 | 91 |
| 102 | Preparative Cytoreductive Surgery in Patients with Metastatic Renal Cell Carcinoma Treated with Adoptive Immunotherapy with Interleukin-2 or Interleukin-2 Plus Lymphokine Activated Killer Cells. Journal of Urology, 1990, 144, 614-617. | 0.2 | 90 |
| 103 | Partial adrenalectomy: The National Cancer Institute experience. Urology, 2005, 66, 19-23. | 0.5 | 89 |
| 104 | New Strategies in Renal Cell Carcinoma: Targeting the Genetic and Metabolic Basis of Disease. Clinical Cancer Research, 2015, 21, 10-17. | 3.2 | 88 |
| 105 | Original Articles: Kidney Cancer: Parenchymal Sparing Surgery in Patients With Hereditary Renal Cell Carcinoma. Journal of Urology, 1995, 153, 913-916. | 0.2 | 87 |
| 106 | Targeting ABL1-Mediated Oxidative Stress Adaptation in Fumarate Hydratase-Deficient Cancer. Cancer Cell, 2014, 26, 840-850. | 7.7 | 87 |
| 107 | Detection of an Immunogenic HERV-E Envelope with Selective Expression in Clear Cell Kidney Cancer. Cancer Research, 2016, 76, 2177-2185. | 0.4 | 86 |
| 108 | Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location. Human Mutation, 2004, 23, 40-46. | 1.1 | 85 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Germline PTEN Mutation Cowden Syndrome: An Underappreciated Form of Hereditary Kidney Cancer. Journal of Urology, 2013, 190, 1990-1998. | 0.2 | 85 |
| 110 | Diagnosis and management of BHD-associated kidney cancer. Familial Cancer, 2013, 12, 397-402. | 0.9 | 85 |
| 111 | Folliculin Controls Lung Alveolar Enlargement and Epithelial Cell Survival through E-Cadherin, LKB1, and AMPK. Cell Reports, 2014, 7, 412-423. | 2.9 | 84 |
| 112 | Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nature Communications, 2021, 12, 808. | 5.8 | 84 |
| 113 | Endolymphatic sac tumors in von Hippelâ€"Lindau disease. Journal of Neurosurgery, 2004, 100, 480-487. | 0.9 | 83 |
| 114 | Salvage Partial Nephrectomy for Hereditary Renal Cancer: Feasibility and Outcomes. Journal of Urology, 2008, 179, 67-70. | 0.2 | 83 |
| 115 | Association of Germline Mutations in the Fumarate Hydratase Gene and Uterine Fibroids in Women With Hereditary Leiomyomatosis and Renal Cell Cancer. Archives of Dermatology, 2008, 144, 1584-92. | 1.7 | 83 |
| 116 | Regulation of Mitochondrial Oxidative Metabolism by Tumor Suppressor FLCN. Journal of the National Cancer Institute, 2012, 104, 1750-1764. | 3.0 | 82 |
| 117 | Tumor suppressor FLCN inhibits tumorigenesis of a FLCN-null renal cancer cell line and regulates expression of key molecules in TGF-Î² signaling. Molecular Cancer, 2010, 9, 160. | 7.9 | 81 |
| 118 | Development of a prostate cDNA microarray and statistical gene expression analysis package. , 2000, 28, 12-22. | | 80 |
| 119 | Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights. European Urology, 2019, 76, 754-764. | 0.9 | 80 |
| 120 | Metabolic Reprogramming for Producing Energy and Reducing Power in Fumarate Hydratase Null Cells from Hereditary Leiomyomatosis Renal Cell Carcinoma. PLoS ONE, 2013, 8, e72179. | 1.1 | 80 |
| 121 | EXPRESSION STUDIES AND MUTATIONAL ANALYSIS OF THE ANDROGEN REGULATED HOMEOBOX GENE NKX3.1 IN BENIGN AND MALIGNANT PROSTATE EPITHELIUM. Journal of Urology, 2001, 165, 1329-1334. | 0.2 | 79 |
| 122 | Discovering Targets of Non-enzymatic Acylation by Thioester Reactivity Profiling. Cell Chemical Biology, 2017, 24, 231-242. | 2.5 | 79 |
| 123 | ONC201 kills breast cancer cellsin vitroby targeting mitochondria. Oncotarget, 2018, 9, 18454-18479. | 0.8 | 77 |
| 124 | A chemoproteomic portrait of the oncometabolite fumarate. Nature Chemical Biology, 2019, 15, 391-400. | 3.9 | 77 |
| 125 | Englerin A Stimulates PKCÎ¸ to Inhibit Insulin Signaling and to Simultaneously Activate HSF1: Pharmacologically Induced Synthetic Lethality. Cancer Cell, 2013, 23, 228-237. | 7.7 | 74 |
| 126 | Folliculin-interacting proteins Fnip1 and Fnip2 play critical roles in kidney tumor suppression in cooperation with Flcn. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1624-31. | 3.3 | 74 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Dynamic Imaging of LDH Inhibition in Tumors Reveals Rapid InÂVivo Metabolic Rewiring and Vulnerability to Combination Therapy. Cell Reports, 2020, 30, 1798-1810.e4. | 2.9 | 73 |
| 128 | Fe-S cofactors in the SARS-CoV-2 RNA-dependent RNA polymerase are potential antiviral targets. Science, 2021, 373, 236-241. | 6.0 | 71 |
| 129 | Genotype-Phenotype Correlation in von Hippel-Lindau Disease With Retinal Angiomatosis. JAMA Ophthalmology, 2007, 125, 239. | 2.6 | 70 |
| 130 | Acute loss of ironâ€“sulfur clusters results in metabolic reprogramming and generation of lipid droplets in mammalian cells. Journal of Biological Chemistry, 2018, 293, 8297-8311. | 1.6 | 70 |
| 131 | Regulatory Effects of microRNA-92 (miR-92) on VHL Gene Expression and the Hypoxic Activation of miR-210 in Clear Cell Renal Cell Carcinoma. Journal of Cancer, 2011, 2, 515-526. | 1.2 | 69 |
| 132 | Studying Cancer Families to Identify Kidney Cancer Genes. Annual Review of Medicine, 2003, 54, 217-233. | 5.0 | 66 |
| 133 | Targeting the Met signaling pathway in renal cancer. Expert Review of Anticancer Therapy, 2009, 9, 785-793. | 1.1 | 66 |
| 134 | Initial Experience With Robot Assisted Partial Nephrectomy for Multiple Renal Masses. Journal of Urology, 2009, 182, 1280-1286. | 0.2 | 66 |
| 135 | Functional and Oncologic Outcomes of Partial Adrenalectomy for Pheochromocytoma in Patients With von Hippel-Lindau Syndrome After at Least 5 Years of Followup. Journal of Urology, 2010, 184, 1855-1859. | 0.2 | 66 |
| 136 | Superiority of 68Ga-DOTATATE over 18F-FDG and anatomic imaging in the detection of succinate dehydrogenase mutation (SDHx )-related pheochromocytoma and paraganglioma in the pediatric population. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 787-797. | 3.3 | 64 |
| 137 | Mitochondrial DNA alterations underlie an irreversible shift to aerobic glycolysis in fumarate hydrataseâ€“deficient renal cancer. Science Signaling, 2021, 14, . | 1.6 | 64 |
| 138 | Imaging Features of Hereditary Papillary Renal Cancers. Journal of Computer Assisted Tomography, 1997, 21, 737-741. | 0.5 | 63 |
| 139 | Metabolism of Kidney Cancer: From the Lab to Clinical Practice. European Urology, 2013, 63, 244-251. | 0.9 | 61 |
| 140 | Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. Clinical Genitourinary Cancer, 2019, 17, 1-6. | 0.9 | 60 |
| 141 | Robot-Assisted Laparoscopic Partial Adrenalectomy for Pheochromocytoma: The National Cancer Institute Technique. European Urology, 2011, 60, 118-124. | 0.9 | 58 |
| 142 | Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma. Clinical Cancer Research, 2018, 24, 5977-5989. | 3.2 | 58 |
| 143 | Tumor-Specific Hypermethylation of Epigenetic Biomarkers, Including SFRP1, Predicts for Poorer Survival in Patients from the TCGA Kidney Renal Clear Cell Carcinoma (KIRC) Project. PLoS ONE, 2014, 9, e85621. | 1.1 | 58 |
| 144 | The folliculin-FNIP1 pathway deleted in human Birt-Hogg-DubÃ© syndrome is required for murine B-cell development. Blood, 2012, 120, 1254-1261. | 0.6 | 57 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance drug binding. Nature Communications, 2016, 7, 12037. | 5.8 | 56 |
| 146 | Gender Specific Mutation Incidence and Survival Associations in Clear Cell Renal Cell Carcinoma (CCRCC). PLoS ONE, 2015, 10, e0140257. | 1.1 | 56 |
| 147 | The UOK 257 cell line: a novel model for studies of the human Birtâ€“Hoggâ€“DubÃ© gene pathway. Cancer Genetics and Cytogenetics, 2008, 180, 100-109. | 1.0 | 55 |
| 148 | A novel fumarate hydratase-deficient HLRCC kidney cancer cell line, UOK268: a model of the Warburg effect in cancer. Cancer Genetics, 2012, 205, 377-390. | 0.2 | 55 |
| 149 | MicroRNAâ€204â€5p: A novel candidate urinary biomarker of Xp11.2 translocation renal cell carcinoma. Cancer Science, 2019, 110, 1897-1908. | 1.7 | 55 |
| 150 | Folliculin (Flcn) inactivation leads to murine cardiac hypertrophy through mTORC1 deregulation. Human Molecular Genetics, 2014, 23, 5706-5719. | 1.4 | 54 |
| 151 | Differential expression of the mismatch repair genehMSH2 in malignant prostate tissue is associated with cancer recurrence. Cancer, 2002, 94, 690-699. | 2.0 | 53 |
| 152 | Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer.. Journal of Clinical Oncology, 2020, 38, 5004-5004. | 0.8 | 53 |
| 153 | Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy. Expert Opinion on Biological Therapy, 2008, 8, 779-790. | 1.4 | 51 |
| 154 | Identification of intragenic deletions and duplication in the FLCN gene in Birtâ€Hoggâ€DubÃ© syndrome. Genes Chromosomes and Cancer, 2011, 50, 466-477. | 1.5 | 50 |
| 155 | VHL loss of function and its impact on oncogenic signaling networks in clear cell renal cell carcinoma. International Journal of Biochemistry and Cell Biology, 2009, 41, 753-756. | 1.2 | 49 |
| 156 | Loss of heterozygosity on the short arm of chromosome 3 in sporadic, von hippel-lindau disease-associated, and familial pheochromocytoma. Genes Chromosomes and Cancer, 1995, 13, 151-156. | 1.5 | 48 |
| 157 | Management of von Hippelâ€“Lindau-associated kidney cancer. Nature Reviews Urology, 2005, 2, 248-255. | 1.4 | 48 |
| 158 | Robot-assisted Laparoscopic Partial Adrenalectomy: Initial Experience. Urology, 2011, 77, 775-780. | 0.5 | 47 |
| 159 | Evaluation of Color Doppler Intraoperative Ultrasound in Parenchymal Sparing Renal Surgery. Journal of Urology, 1994, 152, 1984-1987. | 0.2 | 44 |
| 160 | Intratumoral heterogeneity in kidney cancer. Nature Genetics, 2014, 46, 214-215. | 9.4 | 44 |
| 161 | Association of VHL Genotype With Pancreatic Neuroendocrine Tumor Phenotype in Patients With von Hippelâ€“Lindau Disease. JAMA Oncology, 2018, 4, 124. | 3.4 | 44 |
| 162 | The genetic basis of cancer of kidney cancer: implications for gene-specific clinical management. BJU International, 2005, 95, 2-7. | 1.3 | 43 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Clinical features, genetics and potential therapeutic approaches for Birtâ€“Hoggâ€“DubÃ© syndrome. Expert Opinion on Orphan Drugs, 2015, 3, 15-29. | 0.5 | 43 |
| 164 | Metabolic Pathways in Kidney Cancer: Current Therapies and Future Directions. Journal of Clinical Oncology, 2018, 36, 3540-3546. | 0.8 | 41 |
| 165 | The Genetic Basis of Pheochromocytoma and Paraganglioma: Implications for Management. Urology, 2014, 83, 1225-1232. | 0.5 | 40 |
| 166 | Phase II study of the oral HIF-2Î± inhibitor MK-6482 for Von Hippel-Lindau diseaseâ€“associated renal cell carcinoma.. Journal of Clinical Oncology, 2020, 38, 5003-5003. | 0.8 | 40 |
| 167 | Growth Rates of Genetically Defined Renal Tumors: Implications for Active Surveillance and Intervention. Journal of Clinical Oncology, 2020, 38, 1146-1153. | 0.8 | 39 |
| 168 | Post-translational Regulation of FNIP1 Creates a Rheostat for the Molecular Chaperone Hsp90. Cell Reports, 2019, 26, 1344-1356.e5. | 2.9 | 38 |
| 169 | Improved detection of germline mutations in the von Hippelâ€Lindau disease tumor suppressor gene. Human Mutation, 1998, 12, 417-423. | 1.1 | 38 |
| 170 | Biological and clinical impact of hemangioblastoma-associated peritumoral cysts in von Hippel-Lindau disease. Journal of Neurosurgery, 2016, 124, 971-976. | 0.9 | 37 |
| 171 | Multi-regional Sequencing Elucidates the Evolution of Clear Cell Renal Cell Carcinoma. Cell, 2018, 173, 540-542. | 13.5 | 37 |
| 172 | Non-Clear Cell Renal Cancer: Disease-Based Management and Opportunities for Targeted Therapeutic Approaches. Seminars in Oncology, 2013, 40, 511-520. | 0.8 | 36 |
| 173 | Impact of Ischemia and Procurement Conditions on Gene Expression in Renal Cell Carcinoma. Clinical Cancer Research, 2013, 19, 42-49. | 3.2 | 36 |
| 174 | Recommendations for the Management of Rare Kidney Cancers. European Urology, 2017, 72, 974-983. | 0.9 | 36 |
| 175 | SnapShot: Renal Cell Carcinoma. Cancer Cell, 2016, 29, 610-610.e1. | 7.7 | 35 |
| 176 | PET/CT imaging of renal cell carcinoma with 18F-VM4-037: a phase II pilot study. Abdominal Radiology, 2016, 41, 109-118. | 1.0 | 35 |
| 177 | Targeting loss of the Hippo signaling pathway in NF2-deficient papillary kidney cancers. Oncotarget, 2018, 9, 10723-10733. | 0.8 | 35 |
| 178 | TFE3 Xp11.2 Translocation Renal Cell Carcinoma Mouse Model Reveals Novel Therapeutic Targets and Identifies GPNMB as a Diagnostic Marker for Human Disease. Molecular Cancer Research, 2019, 17, 1613-1626. | 1.5 | 35 |
| 179 | Germline mutations in the Von Hippelâ€Lindau disease (VHL) gene in families from North America, Europe, and Japan. Human Mutation, 1996, 8, 348-357. | 1.1 | 33 |
| 180 | Loss of heterozygosity on the short arm of chromosome 3 in mesothelioma cell lines and solid tumors. Genes Chromosomes and Cancer, 1994, 11, 15-20. | 1.5 | 32 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Targeted therapies for non-clear renal cell carcinoma. Targeted Oncology, 2010, 5, 119-129. | 1.7 | 32 |
| 182 | A Report of Familial Carotid Body Tumors and Multiple Extra-Adrenal Pheochromocytomas. Journal of Urology, 1991, 145, 1040-1042. | 0.2 | 31 |
| 183 | Kidney cancer. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 948-951. | 0.8 | 31 |
| 184 | Pathologic validation of renal cell carcinoma histology in the Surveillance, Epidemiology, and End Results program. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 23.e9-23.e13. | 0.8 | 30 |
| 185 | A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic Renal Cell Carcinoma. Journal of Translational Medicine, 2010, 8, 8. | 1.8 | 29 |
| 186 | Evaluation of Recipients of Positive and Negative Secondary Findings Evaluations in a Hybrid CLIA-Research Sequencing Pilot. American Journal of Human Genetics, 2018, 103, 358-366. | 2.6 | 29 |
| 187 | Glycolytic metabolism of pathogenic T cells enables early detection of GVHD by 13C-MRI. Blood, 2021, 137, 126-137. | 0.6 | 29 |
| 188 | Comedonal and Cystic Fibrofolliculomas in Birt-Hogg-Dube Syndrome. JAMA Dermatology, 2015, 151, 770. | 2.0 | 28 |
| 189 | Germline mutations of renal cancer predisposition genes and clinical relevance in Chinese patients with sporadic, earlyâ€onset disease. Cancer, 2019, 125, 1060-1069. | 2.0 | 28 |
| 190 | Development of a Cell-Based Reporter Assay for Screening of Inhibitors of Hypoxia-Inducible Factor 2-Induced Gene Expression. Journal of Biomolecular Screening, 2006, 11, 678-687. | 2.6 | 25 |
| 191 | Increasing reactive oxygen species as a therapeutic approach to treat hereditary leiomyomatosis and renal cell carcinoma. Cell Cycle, 2010, 9, 4183-4189. | 1.3 | 25 |
| 192 | Loss of Folliculin Disrupts Hematopoietic Stem Cell Quiescence and Homeostasis Resulting in Bone Marrow Failure. Stem Cells, 2016, 34, 1068-1082. | 1.4 | 25 |
| 193 | Repeat Robotic Partial Nephrectomy: Characteristics, Complications, and Renal Functional Outcomes. Journal of Endourology, 2016, 30, 1219-1226. | 1.1 | 25 |
| 194 | Co-opting a Bioorthogonal Reaction for Oncometabolite Detection. Journal of the American Chemical Society, 2016, 138, 15813-15816. | 6.6 | 25 |
| 195 | A deep-learning based artificial intelligence (AI) approach for differentiation of clear cell renal cell carcinoma from oncocytoma on multi-phasic MRI. Clinical Imaging, 2021, 77, 291-298. | 0.8 | 25 |
| 196 | Diagnostic Localization of Malignant Bladder Pheochromocytoma Using 6-[ 18 F]Fluorodopamine Positron Emission Tomography. Journal of Urology, 2003, 169, 274-275. | 0.2 | 24 |
| 197 | Innovations and challenges in renal cancer: Summary statement from the Third Cambridge Conference. Cancer, 2009, 115, 2247-2251. | 2.0 | 24 |
| 198 | Discoveries, therapies and opportunities. Nature Reviews Urology, 2014, 11, 614-616. | 1.9 | 24 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | Association of urinary bladder paragangliomas with germline mutations in the SDHB and VHL genes. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 167.e13-167.e20. | 0.8 | 24 |
| 200 | Patient-specific factors influence somatic variation patterns in von Hippelâ€“Lindau disease renal tumours. Nature Communications, 2016, 7, 11588. | 5.8 | 24 |
| 201 | Using Prostate Imaging-Reporting and Data System (PI-RADS) Scores to Select an Optimal Prostate Biopsy Method: A Secondary Analysis of the Trio Study. European Urology Oncology, 2022, 5, 176-186. | 2.6 | 24 |
| 202 | Therapeutic inhibition of HIF-2Î± reverses polycythemia and pulmonary hypertension in murine models of human diseases. Blood, 2021, 137, 2509-2519. | 0.6 | 24 |
| 203 | Progelatinase A mRNA Expression in cell lines derived from tumors in patients with metastatic renal cell carcinoma correlates inversely with survival. Urology, 1997, 50, 295-301. | 0.5 | 23 |
| 204 | Identification and evaluation of soft coral diterpenes as inhibitors of HIF-2Î± induced gene expression. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 2113-2115. | 1.0 | 23 |
| 205 | The Genetic Basis of Kidney Cancer: Implications for Management and Use of Targeted Therapeutic Approaches. European Urology, 2012, 61, 896-898. | 0.9 | 23 |
| 206 | Mitochondrial DNA mutations distinguish bilateral multifocal renal oncocytomas from familial Birtâ€“Hoggâ€“DubÃ© tumors. Modern Pathology, 2015, 28, 1458-1469. | 2.9 | 23 |
| 207 | Targeting HIF2Î± in Clear-Cell Renal Cell Carcinoma. Cancer Cell, 2016, 30, 515-517. | 7.7 | 23 |
| 208 | Multiple painful cutaneous nodules and renal mass. Journal of the American Academy of Dermatology, 2006, 55, 683-686. | 0.6 | 22 |
| 209 | Atherosclerotic Plaque Burden on Abdominal CT: Automated Assessment With Deep Learning on Noncontrast and Contrast-enhanced Scans. Academic Radiology, 2021, 28, 1491-1499. | 1.3 | 22 |
| 210 | Clinical and Molecular Characterization of Microphthalmia-associated Transcription Factor (MITF)-related Renal Cell Carcinoma. Urology, 2021, 149, 89-97. | 0.5 | 22 |
| 211 | The effect of 4MA, a potent inhibitor of 5 alpha-reductase, on the growth of androgen-responsive human genitourinary tumors grown in athymic nude mice. Prostate, 1987, 10, 189-197. | 1.2 | 21 |
| 212 | Fine-needle aspiration of metastatic clear cell carcinoma of the kidney. Cancer, 1997, 81, 180-186. | 2.0 | 21 |
| 213 | Familial Renal Cancer: Molecular Genetics and Surgical Management. International Journal of Surgical Oncology, 2011, 2011, 1-11. | 0.3 | 21 |
| 214 | Comprehensive genomic and phenotypic characterization of germline FH deletion in hereditary leiomyomatosis and renal cell carcinoma. Genes Chromosomes and Cancer, 2017, 56, 484-492. | 1.5 | 21 |
| 215 | A Phase I Study of Intravesical Suramin for the Treatment of Superficial Transitional Cell Carcinoma of the Bladder. Journal of Urology, 2003, 169, 357-360. | 0.2 | 20 |
| 216 | Impact of Genetics on the Diagnosis and Treatment of Renal Cancer. Current Urology Reports, 2011, 12, 47-55. | 1.0 | 20 |

| # | Article | IF | Citations |
|---|---|---|---|
| 217 | CDC73 Germline Mutation in a Family With Mixed Epithelial and Stromal Tumors. Urology, 2019, 124, 91-97. | 0.5 | 20 |
| 218 | Targeting HIF2Î± Translation with Tempol in VHL-Deficient Clear Cell Renal Cell Carcinoma. Oncotarget, 2012, 3, 1472-1482. | 0.8 | 20 |
| 219 | The tumor suppressor folliculin inhibits lactate dehydrogenase A and regulates the Warburg effect. Nature Structural and Molecular Biology, 2021, 28, 662-670. | 3.6 | 19 |
| 220 | Imaging of glucose metabolism by 13C-MRI distinguishes pancreatic cancer subtypes in mice. ELife, 2019, 8, . | 2.8 | 19 |
| 221 | A pilot trial of chemohormonal therapy for metastatic prostate carcinoma. Cancer, 1992, 69, 213-218. | 2.0 | 18 |
| 222 | Detection of loss of heterozygosity at chromosome 3p25-26 in primary and metastatic ovarian clear-cell carcinoma: Utilization of microdissection and polymerase chain reaction in archival tissues. Diagnostic Cytopathology, 2001, 24, 328-332. | 0.5 | 18 |
| 223 | PARENCHYMAL SPARING SURGERY FOR CENTRAL RENAL TUMORS IN PATIENTS WITH HEREDITARY RENAL CANCERS. Journal of Urology, 2004, 172, 49-53. | 0.2 | 18 |
| 224 | Renal functional outcomes after robotic multiplex partial nephrectomy: the National Cancer Institute experience with robotic partial nephrectomy for 3 or more tumors in a single kidney. International Urology and Nephrology, 2016, 48, 1817-1821. | 0.6 | 18 |
| 225 | A FLCN-TFE3 Feedback Loop Prevents Excessive Glycogenesis and Phagocyte Activation by Regulating Lysosome Activity. Cell Reports, 2020, 30, 1823-1834.e5. | 2.9 | 18 |
| 226 | Genetic Basis of Bilateral Renal Cancer: Implications for Evaluation and Management. Journal of Clinical Oncology, 2009, 27, 3731-3733. | 0.8 | 17 |
| 227 | H255Y and K508R missense mutations in tumour suppressorfolliculin (FLCN)promote kidney cell proliferation. Human Molecular Genetics, 2016, 26, ddw392. | 1.4 | 17 |
| 228 | Blood and lymphatic systems are segregated by the FLCN tumor suppressor. Nature Communications, 2020, 11, 6314. | 5.8 | 17 |
| 229 | Determination of the Expression of PD-L1 in the Morphologic Spectrum of Renal Cell Carcinoma. Journal of Cancer, 2020, 11, 3596-3603. | 1.2 | 17 |
| 230 | Hypoxia-Inducible Factor 2Î± Mutation-Related Paragangliomas Classify as Discrete Pseudohypoxic Subcluster. Neoplasia, 2016, 18, 567-576. | 2.3 | 16 |
| 231 | Photoinducible Oncometabolite Detection. ChemBioChem, 2019, 20, 360-365. | 1.3 | 16 |
| 232 | Inhibition of Hypoxia Inducible Factor-2 Transcription: Isolation of Active Modulators from Marine Sponges. Journal of Natural Products, 2012, 75, 1632-1636. | 1.5 | 15 |
| 233 | Efficacy of Intralesional Botulinum Toxin A for Treatment of Painful Cutaneous Leiomyomas. JAMA Dermatology, 2015, 151, 1096. | 2.0 | 15 |
| 234 | Long-term Functional and Oncologic Outcomes of Partial Adrenalectomy for Pheochromocytoma. Urology, 2020, 140, 85-90. | 0.5 | 15 |

| # | Article | IF | Citations |
|---|---|---|---|
| 235 | Tonantzitlolone cytotoxicity toward renal cancer cells is PKCÎ¸- and HSF1-dependent. Oncotarget, 2015, 6, 29963-29974. | 0.8 | 15 |
| 236 | PSEUDOTUMORS AFTER RENAL PARENCHYMAL SPARING SURGERY. Journal of Urology, 1998, 159, 1148-1151. | 0.2 | 14 |
| 237 | Targeting VEGF receptors in kidney cancer. Lancet Oncology, The, 2007, 8, 956-957. | 5.1 | 14 |
| 238 | Prospective Evaluation of the Clinical Utility of 18-Fluorodeoxyglucose PET CT Scanning in Patients with Von Hippel-Lindauâ€“Associated Pancreatic Lesions. Journal of the American College of Surgeons, 2014, 218, 997-1003. | 0.2 | 14 |
| 239 | RCC â€” advances in targeted therapeutics and genomics. Nature Reviews Urology, 2017, 14, 76-78. | 1.9 | 14 |
| 240 | Genomic and metabolic characterization of a chromophobe renal cell carcinoma cell line model (UOK276). Genes Chromosomes and Cancer, 2017, 56, 719-729. | 1.5 | 14 |
| 241 | BHD-associated kidney cancer exhibits unique molecular characteristics and a wide variety of variants in chromatin remodeling genes. Human Molecular Genetics, 2018, 27, 2712-2724. | 1.4 | 14 |
| 242 | Tobacco smoking induces metabolic reprogramming of renal cell carcinoma. Journal of Clinical Investigation, 2021, 131, . | 3.9 | 14 |
| 243 | A Phase II Trial of Vandetanib in Children and Adults with Succinate Dehydrogenaseâ€“Deficient Gastrointestinal Stromal Tumor. Clinical Cancer Research, 2019, 25, 6302-6308. | 3.2 | 13 |
| 244 | Utilization of microdissection and the polymerase chain reaction for the diagnosis of adrenal cortical carcinoma in fine-needle aspiration cytology. , 1999, 87, 231-237. | | 12 |
| 245 | Partial adrenalectomy in patients with multiple adrenal tumors. Current Urology Reports, 2001, 2, 19-23. | 1.0 | 12 |
| 246 | In silico VHL Gene Mutation Analysis and Prognosis of Pancreatic Neuroendocrine Tumors in von Hippelâ€“Lindau Disease. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1631-1638. | 1.8 | 12 |
| 247 | Pathologic Oxidation of PTPN12 Underlies ABL1 Phosphorylation in Hereditary Leiomyomatosis and Renal Cell Carcinoma. Cancer Research, 2018, 78, 6539-6548. | 0.4 | 12 |
| 248 | Metabolic Labeling of Cultured Mammalian Cells for Stable Isotope-Resolved Metabolomics: Practical Aspects of Tissue Culture and Sample Extraction. Methods in Molecular Biology, 2019, 1928, 1-27. | 0.4 | 12 |
| 249 | Precision Surgery and Kidney Cancer: Knowledge of Genetic Alterations Influences Surgical Management. Genes, 2021, 12, 261. | 1.0 | 12 |
| 250 | PULMONARY INFARCTS CAN MIMIC PULMONARY METASTASES FROM RENAL CANCER. Journal of Urology, 1997, 158, 1688-1690. | 0.2 | 11 |
| 251 | Long term outcomes for patients with von Hippel-Lindau and Pheochromocytoma: defining the role of active surveillance. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 134.e1-134.e8. | 0.8 | 11 |
| 252 | Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement. Cancer, 2021, 127, 3957-3966. | 2.0 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 253 | Haploinsufficiency in tumor predisposition syndromes: altered genomic transcription in morphologically normal cells heterozygous for VHL or TSC mutation. Oncotarget, 2017, 8, 17628-17642. | 0.8 | 11 |
| 254 | Molecular Genetics of Tumor Suppressor Genes in Prostate Carcinoma: the Challenge and the Promise Ahead. Journal of Urology, 1992, 147, 808-809. | 0.2 | 10 |
| 255 | Isolated perfusion of the kidney with tumor necrosis factor for localized renal-cell carcinoma. World Journal of Urology, 1996, 14, S2-7. | 1.2 | 10 |
| 256 | Proteasome inhibition disrupts the metabolism of fumarate hydratase- deficient tumors by downregulating p62 and c-Myc. Scientific Reports, 2019, 9, 18409. | 1.6 | 10 |
| 257 | Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome: Spectrum of imaging findings. Clinical Imaging, 2020, 68, 14-19. | 0.8 | 10 |
| 258 | Clear Cell Renal Cell Carcinoma Growth Correlates with Baseline Diffusion-weighted MRI in Von Hippelâ€“Lindau Disease. Radiology, 2020, 295, 583-590. | 3.6 | 10 |
| 259 | Characterization of genetically defined sporadic and hereditary type 1 papillary renal cell carcinoma cell lines. Genes Chromosomes and Cancer, 2021, 60, 434-446. | 1.5 | 10 |
| 260 | Reoperative Partial Nephrectomyâ€”Does Previous Surgical Footprint Impact Outcomes?. Journal of Urology, 2021, 206, 539-547. | 0.2 | 10 |
| 261 | Persistent Severe Hyperlactatemia and Metabolic Derangement in Lethal SDHB-Mutated Metastatic Kidney Cancer: Clinical Challenges and Examples of Extreme Warburg Effect. JCO Precision Oncology, 2017, 1, 1-14. | 1.5 | 9 |
| 262 | Birt-Hogg-DubÃ© syndrome initially diagnosed as tuberous sclerosis complex. JAAD Case Reports, 2019, 5, 368-371. | 0.4 | 9 |
| 263 | Dual functions of angiopoietin-like protein 2 signaling in tumor progression and anti-tumor immunity. Genes and Development, 2019, 33, 1641-1656. | 2.7 | 9 |
| 264 | PARENCHYMAL SPARING SURGERY IN A PATIENT WITH MULTIPLE BILATERAL PAPILLARY RENAL CANCER. Journal of Urology, 2001, 165, 1623-1624. | 0.2 | 8 |
| 265 | Use of nephron-sparing surgery among renal cell carcinoma patients with diabetes and hypertension. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 27.e15-27.e21. | 0.8 | 8 |
| 266 | Biodistribution and Efficacy of Low Temperature-Sensitive Liposome Encapsulated Docetaxel Combined with Mild Hyperthermia in a Mouse Model of Prostate Cancer. Pharmaceutical Research, 2016, 33, 2459-2469. | 1.7 | 8 |
| 267 | Insights into Epigenetic Remodeling in VHL-Deficient Clear Cell Renal Cell Carcinoma. Cancer Discovery, 2017, 7, 1221-1223. | 7.7 | 8 |
| 268 | A germline 1;3 translocation disrupting the VHL gene: a novel genetic cause for von Hippel-Lindau. Journal of Medical Genetics, 2020, , jmedgenet-2020-107308. | 1.5 | 8 |
| 269 | MPAPASS software enables stitched multiplex, multidimensional EV repertoire analysis and a standard framework for reporting bead-based assays. Cell Reports Methods, 2022, 2, 100136. | 1.4 | 8 |
| 270 | Postoperative elevation in creatine kinase and its impact on renal function in patients undergoing complex partial nephrectomy. International Urology and Nephrology, 2016, 48, 1047-1053. | 0.6 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 271 | Vascular Endothelial Growth Factor Receptorâ€“Targeted Therapy in Succinate Dehydrogenase C Kidney Cancer. Journal of Clinical Oncology, 2016, 34, e76-e79. | 0.8 | 7 |
| 272 | Mithramycin A Enhances Tumor Sensitivity to Mitotic Catastrophe Resulting From DNA Damage. International Journal of Radiation Oncology Biology Physics, 2018, 100, 344-352. | 0.4 | 7 |
| 273 | Cumulative Radiation Exposures from CT Screening and Surveillance Strategies for von Hippel-Lindauâ€“associated Solid Pancreatic Tumors. Radiology, 2019, 290, 116-124. | 3.6 | 7 |
| 274 | Heterogeneous adaptation of cysteine reactivity to a covalent oncometabolite. Journal of Biological Chemistry, 2020, 295, 13410-13418. | 1.6 | 7 |
| 275 | Novel renal medullary carcinoma cell lines, <scp>UOK353</scp> and <scp>UOK360</scp>, provide preclinical tools to identify new therapeutic treatments. Genes Chromosomes and Cancer, 2020, 59, 472-483. | 1.5 | 7 |
| 276 | Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. , 2000, 21, 2235. | | 7 |
| 277 | The origin, evolution and route to metastasis of clear cell RCC. Nature Reviews Nephrology, 2018, 14, 538-540. | 4.1 | 6 |
| 278 | Comprehensive characterization of Alu â€mediated breakpoints in germline VHL gene deletions and rearrangements in patients from 71 VHL families. Human Mutation, 2021, 42, 520-529. | 1.1 | 6 |
| 279 | X-Capsular Incision for Tumor Enucleation (X-CITE)-Technique: A Method to Maximize Renal Parenchymal Preservation for Completely Endophytic Renal Tumors. Urology, 2021, 154, 315-319. | 0.5 | 6 |
| 280 | Obstructive azoospermia secondary to bilateral epididymal cystadenomas in a patient with von Hippel-Lindau. Urology Case Reports, 2019, 27, 100922. | 0.1 | 5 |
| 281 | FLCN alteration drives metabolic reprogramming towards nucleotide synthesis and cyst formation in salivary gland. Biochemical and Biophysical Research Communications, 2020, 522, 931-938. | 1.0 | 5 |
| 282 | Intravitreous treatment of severe ocular von <scp>Hippelâ€“Lindau</scp> disease using a combination of the <scp>VEGF</scp> inhibitor, ranibizumab and <scp>PDGF</scp> inhibitor, <scp>E10030</scp>: Results from a phase 1/2 clinical trial. Clinical and Experimental Ophthalmology, 2021, 49, 1048-1059. | 1.3 | 5 |
| 283 | Renal Cell Carcinoma. Journal of Urology, 1988, 139, 340-341. | 0.2 | 4 |
| 284 | Flow cytometric DNA analysis of interleukin-2 responsive renal cell carcinoma. Journal of Surgical Oncology, 1993, 53, 252-255. | 0.8 | 4 |
| 285 | Allelic Loss on Chromosome 8p in BRCA-1 Mutation Positive Breast/Ovarian Cancers. Breast Journal, 1998, 4, 9-12. | 0.4 | 4 |
| 286 | Kidney cancer: Opportunity for disease specific targeted therapy. Urologic Oncology: Seminars and Original Investigations, 2008, 26, 542. | 0.8 | 4 |
| 287 | Differential Genetic Expression in Large Versus Small Clear Cell Renal Cell Carcinoma: Results from Microarray Analysis. Journal of Cancer, 2011, 2, 271-279. | 1.2 | 4 |
| 288 | Treating advanced kidney cancerâ€”miles to go before we sleep. Nature Reviews Clinical Oncology, 2013, 10, 614-615. | 12.5 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 289 | Looking forward, looking backâ€”10 years in urology. Nature Reviews Urology, 2014, 11, 649-655. | 1.9 | 4 |
| 290 | Metabolism and Oxidative Stress Response Pathways in Kidney Cancer: A Tale of Chance and Necessity. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , 220-225. | 1.8 | 4 |
| 291 | The Warburg effect in hominis: isotope-resolved metabolism in ccRCC. Nature Reviews Urology, 2018, 15, 731-732. | 1.9 | 4 |
| 292 | An Oncometabolite Isomer Rapidly Induces a Pathophysiological Protein Modification. ACS Chemical Biology, 2020, 15, 856-861. | 1.6 | 4 |
| 293 | 18Fluorodeoxyglucose-positron emission tomography/computed tomography for differentiation of renal tumors in hereditary kidney cancer syndromes. Abdominal Radiology, 2021, 46, 3301-3308. | 1.0 | 4 |
| 294 | Treatment of Advanced Renal Cell Carcinoma. , 2012, , 1475-1491.e5. | | 4 |
| 295 | Seventh BHD international symposium: recent scientific and clinical advancement. Oncotarget, 2022, 13, 173-181. | 0.8 | 4 |
| 296 | Single-cell transcriptomes underscore genetically distinct tumor characteristics and microenvironment for hereditary kidney cancers. IScience, 2022, 25, 104463. | 1.9 | 4 |
| 297 | Inhibition of HSP 90 is associated with potent anti-tumor activity in Papillary Renal Cell Carcinoma. Journal of Experimental and Clinical Cancer Research, 2022, 41, . | 3.5 | 4 |
| 298 | A mouse model of renal cell carcinoma. Nature Medicine, 2017, 23, 802-803. | 15.2 | 3 |
| 299 | Differences in Tumor VHL Mutation and Hypoxia-inducible Factor 2Î± Expression Between African American and White Patients with Clear Cell Renal Cell Carcinoma. European Urology, 2019, 75, 882-884. | 0.9 | 3 |
| 300 | Phase II trial of vandetanib in Von Hippel-Lindau-associated renal cell carcinoma.. Journal of Clinical Oncology, 2013, 31, 4584-4584. | 0.8 | 3 |
| 301 | Clinical evaluation of 2-(18F) fluoro-2 deoxy-D-glucose PET/ CT in hereditary leiomyomatosis and renal cell carcinoma.. Journal of Clinical Oncology, 2013, 31, 383-383. | 0.8 | 3 |
| 302 | Targeting chemoresistance in Xp11.2 translocation renal cell carcinoma using a novel polyamideâ€“chlorambucil conjugate. Cancer Science, 2022, 113, 2352-2367. | 1.7 | 3 |
| 303 | Fumarate hydratase-deficient renal cell carcinoma cells respond to asparagine by activation of the unfolded protein response and stimulation of the hexosamine biosynthetic pathway. Cancer & Metabolism, 2020, 8, 7. | 2.4 | 2 |
| 304 | MicroRNA Profiling of Morphologically Heterogeneous Clear Cell Renal Cell Carcinoma. Journal of Cancer, 2021, 12, 5375-5384. | 1.2 | 2 |
| 305 | Rapid protein display profiling of cancer progression directly from human tissue using a protein biochip. , 2000, 49, 34. | | 2 |
| 306 | Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. , 2000, 21, 2235. | | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 307 | Defining early-onset kidney cancer: Implications for genetic counseling.. Journal of Clinical Oncology, 2013, 31, 342-342. | 0.8 | 2 |
| 308 | Differential VHL Mutation Patterns in Bilateral Clear Cell RCC Distinguishes Between Independent Primary Tumors and Contralateral Metastatic Disease. Urology, 2022, 165, 170-177. | 0.5 | 2 |
| 309 | A Histone Deacetylase Inhibitor Induces Acetyl-CoA Depletion Leading to Lethal Metabolic Stress in RAS-Pathway Activated Cells. Cancers, 2022, 14, 2643. | 1.7 | 2 |
| 310 | Editorial Comment. Urology, 2014, 83, 675.e5. | 0.5 | 1 |
| 311 | The Metabolic Basis of Kidney Cancer. , 2015, , 89-102. | | 1 |
| 312 | Managing Renal Cell Carcinoma Associated Paraneoplastic Syndrome with Nephron-sparing Surgery in a Patient with von Hippel-Lindau. Urology Case Reports, 2017, 13, 101-103. | 0.1 | 1 |
| 313 | Multiple Recurrent Paraganglioma in a Pediatric Patient with Germline SDH-B Mutation. Urology Case Reports, 2017, 13, 107-109. | 0.1 | 1 |
| 314 | Salvage Surgery After Percutaneous Ablation of Renal Mass in Solitary Kidney in a Patient With Von Hippel-Lindau. Clinical Genitourinary Cancer, 2019, 17, e482-e484. | 0.9 | 1 |
| 315 | Hereditary Renal Cell Carcinoma. , 2017, , 19-82. | | 1 |
| 316 | Serial analysis of gene expression in renal carcinoma cells reveals VHL-dependent sensitivity to TNFÎ± cytotoxicity. , 0, . | | 1 |
| 317 | Paragangliomas of the urinary bladder: Experience at the National Cancer Institute.. Journal of Clinical Oncology, 2013, 31, 307-307. | 0.8 | 1 |
| 318 | Aids Case for Diagnosis, 1986 Military Medicine. Military Medicine, 1986, 151, M49-M56. | 0.4 | 0 |
| 319 | Identification of the genes for kidney cancer. Cancer Biology and Therapy, 2006, 5, 696-699. | 1.5 | 0 |
| 320 | Salvage robotic transmesenteric off-clamp partial nephrectomy after multiple prior open kidney surgeries. Urology Case Reports, 2020, 30, 101135. | 0.1 | 0 |
| 321 | Macronodular adrenal hyperplasia masquerading as an upper pole renal mass. Urology Case Reports, 2021, 37, 101603. | 0.1 | 0 |
| 322 | Protein expression profiling in the spectrum of renal tumors. FASEB Journal, 2007, 21, A181. | 0.2 | 0 |
| 323 | Metabolic evaluation of sporadic papillary kidney cancer.. Journal of Clinical Oncology, 2012, 30, 377-377. | 0.8 | 0 |